Theranos Elizabeth Holmes Hasn’t Been Paying Legal Fees in Civil Case, Palo Alto Lawyer Says

Former Theranos CEO Elizabeth Holmes walks to federal court for a status hearing on July 17, 2019, in San Jose, Calif. Holmes is facing charges of conspiracy and wire fraud for allegedly engaging in a multimillion-dollar scheme to defraud investors with the Theranos blood testing lab services. (Credit: Kimberly White/Getty Images)

Former Theranos CEO Elizabeth Holmes walks to federal court for a status hearing on July 17, 2019, in San Jose, Calif. Holmes is facing charges of conspiracy and wire fraud for allegedly engaging in a multimillion-dollar scheme to defraud investors with the Theranos blood testing lab services. (Credit: Kimberly White/Getty Images)

The founder of scandalized blood-testing startup Theranos is now being accused of skipping out on bills owed to the lawyers defending her against fraud charges in a civil lawsuit.

Elizabeth Holmes, who ran Theranos until its 2018 collapse, hasn’t paid her Palo Alto, California, attorney John Dwyer and his colleagues for the past year, according to documents filed Monday in Phoenix federal court. The lawyers want to quit the case because they don’t ever expect to be paid. The documents cited Holmes “current financial situation” without elaborating.

Dwyer didn’t immediately respond to a request for comment Friday. A message left for Holmes’ attorney in a separate criminal case in San Jose, California, wasn’t immediately returned. Holmes has pleaded not guilty to the criminal charges of conspiracy and fraud in a case that is scheduled to go to trial next summer.

A trial date hasn’t been set for the civil lawsuit filed against Holmes, Theranos and Walgreens, which offered Theranos’ blood-testing technology in Arizona and California. The lawsuit was filed on behalf of consumers who paid for Theranos’ blood testing service.

Holmes, a former Stanford University student, started Theranos in Palo Alto on the promise it had developed a way to perform complex blood analysis with a finger prick. Federal authorities asserted that Theranos’ technology didn’t work as advertised, duping both the company’s investors and customers.

Notice: you are using an outdated browser. Microsoft does not recommend using IE as your default browser. Some features on this website, like video and images, might not work properly. For the best experience, please upgrade your browser.